Krystal Biotech Reports $96M Q2 Revenue Expands Japan, Europe

Krystal Biotech reported strong financial results for Q2 2025, with VYJUVEK generating $96 million in revenue and a gross margin of 93%, supported by over 575 U.S. reimbursement approvals and new approvals in Japan and Europe. The company’s net income rose significantly to $38.3 million, up from $15.6 million the previous year, while investing heavily in expansion reflected in increased selling, general, and administrative expenses. Analysts forecasted a 171.7% year-over-year increase in EPS to $1.44 and revenue growth of approximately 30.8%, with a consensus 'Outperform' rating and an average price target suggesting a 32.67% upside. Krystal Biotech’s global expansion plans, particularly launching VYJUVEK in Germany and France by the end of 2025, position it strongly in the genetic medicine market. Despite mixed past earnings results, the company maintains investor confidence due to its product success, pipeline development, and expanding market presence.